

Dépistage du cancer du sein: Doit-on réévaluer son efficacité? / Neubewertung des Mammographie-Screening-Nutzens?

Literatur (Online-Version) / Références (online version)

- 1 International Agency for Research on Cancer. Breast cancer screening. Vainio H, Bianchini F, editors. Lyon: IARC Press, 2002.
- 2 Wilson J, Jungner G. Principles and practices of screening for diseases. Geneva, Switzerland: World Health Organisation, 1968.
- 3 Strong K, Wald N, Miller A, Alwan A. Current concepts in screening for noncommunicable disease: World Health Organization Consultation Group Report on methodology of noncommunicable disease screening. *J Med Screen* 2005; 12 (1): 12-9.
- 4 Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: an update for the U.S. Preventive Services Task Force. *Ann Intern Med* 2009; 151 (10): 727-37, W237-42.
- 5 Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? *Lancet* 2000; 355 (9198): 129-34.
- 6 Jorgensen KJ, Keen JD, Gotzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? *Radiology* 2011; 260 (3): 621-7.
- 7 Council of the European Union. Council recommendation of 2 December 2003 on cancer screening (2003/878/EC). *Off J Eur Union* 2003; L 327: 34-8.
- 8 Kirkpatrick A, Törnberg S, Thijssen MAO. European guidelines for quality assurance in mammography screening. Luxembourg: Office for Official Publications of the European Communities, 1993.
- 9 Bulliard J-L, De Landtsheer J-P, Levi F. Results from the Swiss mammography screening pilot programme. *Eur J Cancer* 2003; 38 (12): 1760-8.
- 10 Paap E, Holland R, den Heeten GJ, van Schoor G, Botterweck AA, Verbeek AL, et al. A remarkable reduction of breast cancer deaths in screened versus unscreened women: a case-referent study. *Cancer Causes Control* 2010; 21 (10): 1569-73.
- 11 Autier P, Boniol M, Gavin A, Vatten LJ. Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. *BMJ* 2011; 343: d4411.
- 12 Gøtzsche P, Nielsen M. Screening for breast cancer with mammography. *Cochrane Data Syst Rev*. 2011; 1: CD001877. Available from: www2.cochrane.org/reviews.
- 13 Levi F, Lucchini F, Negri E, La Vecchia C. The fall in breast cancer mortality in Europe. *Eur J Cancer* 2001; 37 (11): 1409-12.
- 14 Harris R, Yeatts J, Kinsinger L. Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. *Prev Med* 2011; 53 (3): 108-14.
- 15 Hanley JA. Measuring mortality reductions in cancer screening trials. *Epidemiol Rev* 2011; 33 (1): 36-45.
- 16 Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. *N Engl J Med* 2010; 363 (13): 1203-10.
- 17 Van Oyen H, Verellen W. Breast cancer screening in the Flemish region, Belgium. *Eur J Cancer Prev* 1994; 3 Suppl 1: 7-12.
- 18 Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P. Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy. *Ann Oncol* 2010; 21 (12): 2356-60.
- 19 Broeders MJ, Scharpantgen A, Ascunce N, Gairard B, Olsen AH, Mantellini P, et al. Comparison of early performance indicators for screening projects within the European Breast Cancer Network: 1989-2000. *Eur J Cancer Prev* 2005; 14 (2): 107-16.
- 20 de Gelder R, Bulliard J-L, de Wolf C, Fracheboud J, Draisma G, Schopper D, et al. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. *Eur J Cancer* 2009; 45 (1): 127-38.
- 21 Autier P, Hery C, Haukka J, Boniol M, Byrnes G. Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening. *J Clin Oncol* 2009; 27 (35): 5919-23.
- 22 de Gelder R, Draisma G, Heijnsdijk EA, de Koning HJ. Population-based mammography screening below age 50: balancing radiation-induced vs prevented breast cancer deaths. *Br J Cancer* 2011; 104 (7): 1214-20.

- 23 Bulliard JL, Ducros C, Dayer E, Arzel B, Levi F. Variation in performance in low-volume mammography screening programmes: Experience from Switzerland. *Cancer Epidemiol* 2011; 35 (3): 293-7.
- 24 Lyng E, Olsen AH, Fracheboud J, Patnick J. Reporting of performance indicators of mammography screening in Europe. *Eur J Cancer Prev* 2003; 12 (3): 213-22.
- 25 Hofvind S, Thoresen S, Tretli S. The cumulative risk of a false-positive recall in the Norwegian Breast Cancer Screening Program. *Cancer* 2004; 101 (7): 1501-7.
- 26 Salas D, Ibanez J, Roman R, Cuevas D, Sala M, Ascunce N, et al. Effect of start age of breast cancer screening mammography on the risk of false-positive results. *Prev Med* 2011; 53 (1-2): 76-81.
- 27 Njor SH, Olsen AH, Schwartz W, Vejborg I, Lyng E. Predicting the risk of a false-positive test for women following a mammography screening programme. *J Med Screen* 2007; 14 (2): 94-7.
- 28 Jorgensen KJ, Gotzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. *BMJ* 2009; 339: b2587.
- 29 de Gelder R, Heijnsdijk EA, van Ravesteyn NT, Fracheboud J, Draisma G, de Koning HJ. Interpreting overdiagnosis estimates in population-based mammography screening. *Epidemiol Rev* 2011; 33 (1): 111-21.
- 30 Duffy SW, Lyng E, Jonsson H, Ayyaz S, Olsen AH. Complexities in the estimation of overdiagnosis in breast cancer screening. *Br J Cancer* 2008; 99 (7): 1176-8.
- 31 Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdiagnosis with mammography screening: a systematic review. *Lancet Oncol* 2007; 8 (12): 1129-38.
- 32 Puliti D, Miccinesi G, Paci E. Overdiagnosis in breast cancer: Design and methods of estimation in observational studies. *Prev Med* 2011; 53 (3): 131-3.
- 33 Moss S. Overdiagnosis and overtreatment of breast cancer: overdiagnosis in randomised controlled trials of breast cancer screening. *Breast Cancer Res* 2005; 7 (5): 230-4.
- 34 Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. *BMJ* 2006; 332 (7543): 689-92.
- 35 Paci E, Duffy SW, Giorgi D, Zappa M, Crocetti E, Vezzosi V, et al. Are breast cancer screening programmes increasing rates of mastectomy? Observational study. *BMJ* 2002; 325 (7361): 418.
- 36 Suhrke P, Maehlen J, Schlichting E, Jorgensen KJ, Gotzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. *BMJ* 2011; 343: d4692.
- 37 Paap E, Verbeek AL, Puliti D, Paci E, Broeders MJ. Breast cancer screening case-control study design: impact on breast cancer mortality. *Ann Oncol* 2011; 22: 863-9.
- 38 Autier P, Boniol M, La Vecchia C, Vatten L, Gavin A, Hery C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. *BMJ* 2010; 341: c3620.
- 39 Bosetti C, Bertuccio P, Levi F, Chatenoud L, Negri E, La Vecchia C. The decline in breast cancer mortality in Europe: An update (to 2009). *Breast* 2012; 21: 77-82.
- 40 Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet* 2005; 365 (9472): 1687-717.
- 41 Skaane P. Studies comparing screen-film mammography and full-field digital mammography in breast cancer screening: updated review. *Acta Radiol* 2009; 50 (1): 3-14.
- 42 Duffy SW, Tabar L, Olsen AH, Vitak B, Allgood PC, Chen TH, et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. *J Med Screen* 2010; 17 (1): 25-30.
- 43 Dean PB. Comments and response on the USPSTF recommendation on screening for breast cancer. *Ann Intern Med* 2010; 152 (8): 539; author reply 543-4.
- 44 Europe Against Cancer. European guidelines for quality assurance in breast cancer screening and diagnosis. 4th ed. Perry N, Broeders M, de Wolf C, et al., editors. Luxembourg: Office for Official Publications of the European Communities, 2006.
- 45 Chamot E, Charvet AI, Perneger TV. Who gets screened, and where: a comparison of organised and opportunistic mammography screening in Geneva, Switzerland. *Eur J Cancer* 2007; 43 (3): 576-84.
- 46 Bulliard J-L, De Landtsheer J-P, Levi F. Profile of women not attending in the Swiss Mammography Screening Pilot Programme. *Breast* 2004; 13 (4): 284-9.
- 47 Bordoni A, Probst-Hensch NM, Mazzucchelli L, Spitale A. Assessment of breast cancer opportunistic screening by clinical-pathological indicators: a population-based study. *Br J Cancer* 2009; 101 (11): 1925-31.

- 48 Bulliard J-L, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effectiveness of organised versus opportunistic mammography screening. *Ann Oncol* 2009; 20 (7): 1199-202.
- 49 Bulliard J-L, La Vecchia C, Levi F. Diverging trends in breast cancer mortality within Switzerland. *Ann Oncol* 2006; 17 (1): 57-9.
- 50 Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lütolf U, et al. Geographic variation in breast cancer care in Switzerland. *Cancer Epidemiol* 2010; 34 (2): 116-21.
- 51 Office fédéral de la Statistique (OFS), Institut national d'épidémiologie et d'enregistrement du cancer (NICER), Registre Suisse du Cancer de l'Enfant. *Le cancer en Suisse. Etat et évolution de 1983 à 2007*. Neuchâtel: Office fédéral de la statistique (OFS), 2011.